Top Markets
Coin of the day
Opus Genetics, Inc. Opus Genetics, Inc.

Opus Genetics, Inc.

IRD
Rank in Stocks #16217
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on... Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Share Price
$3.70
Last synced: 2026-07-31
Market Cap
$305.87M
Change (1 day)
-3.53%
Change (1 year)
203.66%
Country
US
Trade Opus Genetics, Inc. (IRD)

Category

Dividend yield history for Opus Genetics, Inc. (IRD)
Opus Genetics, Inc. (stock symbol: IRD) dividend yield (TTM) as of 2026: 0
Average dividend yield, last 5 years : 0.00%
Dividend yield history for Opus Genetics, Inc. (IRD) from 2026 to 2026
Dividend Yield at the end of each year (TTM)
Year Dividend Yield Change
Not enough data for the provided dates.
Dividend yields (TTM) for similar companies or competitors
Company Dividend Yield Country
0.00%
US
0.00%
NL
0.00%
US
2.48%
AU
0.00%
CH